Japan’s Fujifilm discontinues development of Avigan as COVID-19 drug

Japan’s Fujifilm Holdings Corp said on Friday it had discontinued the development of its anti-influenza drug Avigan as a COVID-19 treatment.

The company had halted Avigan’s enrolment in a clinical trial in March.